https://www.selleckchem.com/pr....oducts/AZD2281(Olapa
55, 95% CI 1.12-2.15 and HR 2.57, 95% CI 1.89-3.48, respectively). After adjustment, rEF was associated with an increased risk of subsequent HF hospitalisation (HR 2.32, 95% CI 1.75-3.08). One in five patients post-ACS have mrEF, which is associated with an intermediate risk of morbidity and mortality compared to those with pEF and rEF. Further study is warranted to determine the optimal management for these patients. One in five patients post-ACS have mrEF, which is associated with an intermediate risk of morbidity and mortal
Like
Comment
Share
